Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial



      To determine whether hypertriglyceridemia is associated with systemic inflammation, which may contribute to the increased cardiovascular risk in patients who have hypertriglyceridemia. In addition, we investigated whether fibrates reverse this inflammatory state.

      Patients and methods

      Serum lipid levels, body mass index, insulin resistance, and inflammatory parameters were compared between 18 patients who had severe hypertriglyceridemia without cardiovascular disease and 20 normolipidemic controls. We measured the ex vivo production capacity of tumor necrosis factor (TNF)-α and interleukin (IL)-6 after whole-blood stimulation with lipopolysaccharide, as well as circulating levels of C-reactive protein and fibrinogen. A randomized controlled trial was conducted to determine whether bezafibrate (400 mg administered daily for 6 weeks) affected these parameters in hypertriglyceridemic patients.


      When compared with normolipidemic controls, hypertriglyceridemic patients had significantly lower high-density lipoprotein (HDL) cholesterol and higher triglyceride levels, body mass index, and insulin resistance. In addition, hypertriglyceridemic patients had a significantly higher production capacity of TNF-α (mean difference, 11 700 pg/mL; 95% confidence interval [CI]: 7800 to 15 700 pg/mL]) and IL-6 (mean difference, 20 400 pg/mL; 95% CI: 7800 to 32 900 pg/mL), and higher levels of C-reactive protein (mean difference, 0.8 mg/L; 95% CI: 0.1 to 2.4 mg/L) and fibrinogen (mean difference, 0.8 g/dL; 95% CI: 0.3 to 1.3 g/dL). Bezafibrate therapy significantly increased HDL cholesterol levels, reduced triglyceride and insulin resistance levels, and reduced production capacity of TNF-α and IL-6, as well as levels of C-reactive protein and fibrinogen.


      Systemic inflammation is present in patients who have the clinical phenotype that is associated with severe hypertriglyceridemia, and may contribute to the increased risk of cardiovascular disease in these patients. Bezafibrate has anti-inflammatory effects in these patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ross R
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Ridker P.M
        • Rifai N
        • Pfeffer M.A
        • et al.
        Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
        Circulation. 1998; 98: 839-844
        • Thompson S.G
        • Kienast J
        • Pyke S.D
        • et al.
        Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
        N Engl J Med. 1995; 332: 635-641
        • Ridker P.M
        • Cushman M
        • Stampfer M.J
        • et al.
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        N Engl J Med. 1997; 336: 973-979
        • Maresca G
        • Di Blasio A
        • Marchioli R
        • Di Minno G
        Measuring plasma fibrinogen to predict stroke and myocardial infarction.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1368-1377
        • Austin M.A
        • Hokanson J.E
        • Edwards K.L
        Hypertriglyceridemia as a cardiovascular risk factor.
        Am J Cardiol. 1998; 81: 7B-12B
        • Simpson H.C
        • Mann J.I
        • Meade T.W
        • et al.
        Hypertriglyceridaemia and hypercoagulability.
        Lancet. 1983; 1: 786-790
        • Avellone G
        • Di Garbo V
        • Cordova R
        • et al.
        Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.
        Blood Coagul Fibrinolysis. 1993; 4: 429-433
        • Mohrschladt M.F
        • Weverling-Rijnsburger A.W
        • de Man F.H
        • et al.
        Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
        Atherosclerosis. 2000; 148: 413-419
        • Richards C
        • Gauldie J
        Role of cytokines in the acute phase response.
        in: Aggarwal B.B Puri R.K Human Cytokines: Their Roles in Disease Therapy. Blackwell Science, Cambridge, Massachusetts1995: 253-269
        • Rubins H.B
        • Robins S.J
        • Collins D
        • et al.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
        N Engl J Med. 1999; 341: 410-418
        • Ruotolo G
        • Ericsson C.G
        • Tettamanti C
        • et al.
        Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
        J Am Coll Cardiol. 1998; 32: 1648-1656
        • Robins S.J
        • Collins D
        • Wittes J.T
        • et al.
        Relation of gemfibrozil treatment and lipid levels with major coronary events.
        JAMA. 2001; 285: 1585-1591
        • Devchand P.R
        • Keller H
        • Peters J.M
        • et al.
        The PPAR alpha-leukotriene B4 pathway to inflammation control.
        Nature. 1996; 384: 39-43
        • de Man F.H
        • Weverling-Rijnsburger A.W
        • van der Laarse A
        • et al.
        Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation.
        Arterioscler Thromb Vasc Biol. 2000; 20: 744-750
        • Matthews D.R
        • Hosker J.P
        • Rudenski A.S
        • et al.
        Homeostasis model assessment.
        Diabetologia. 1985; 28: 412-419
        • Von Clauss A
        Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens.
        Acta Haematol. 1957; 17: 237-246
        • Van der Linden M.W
        • Huizinga T.W.J
        • Stoeken D.J
        • et al.
        Determination of tumor necrosis factor α and interleukin 10 production in a whole blood stimulation system.
        J Immunol Methods. 1998; 218: 63-71
        • De Grootte D
        • Zangerle P.F
        • Gevaert Y
        • et al.
        Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, INF-γ and GM-CSF) in whole blood. I. Comparison with isolated PMBC stimulation.
        Cytokine. 1992; 4: 239-248
        • Madej A
        • Okopien B
        • Kowalski J
        • et al.
        Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
        Int J Clin Pharmacol Ther. 1998; 36: 345-349
        • Staels B
        • Koenig W
        • Habib A
        • et al.
        Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
        Nature. 1998; 393: 790-793
        • Cortellaro M
        • Cofrancesco E
        • Boschetti C
        • et al.
        Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
        Thromb Haemost. 2000; 83: 549-553
        • Grundy S.M
        Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.
        Am J Cardiol. 1998; 83: 25F-29F
        • Festa A
        • D’Agostino R.J
        • Howard G
        • et al.
        Chronic subclinical inflammation as part of the insulin resistance syndrome.
        Circulation. 2000; 102: 42-47
        • Yudkin J.S
        • Stehouwer C.D
        • Emeis J.J
        • Coppack S.W
        C-reactive protein in healthy subjects.
        Arterioscler Thromb Vasc Biol. 1999; 19: 972-978
        • Lemieux I
        • Pascot A
        • Prud’homme D
        • et al.
        Elevated C-reactive protein.
        Arterioscler Thromb Vasc Biol. 2001; 21: 961-967
        • Levine D.M
        • Parker T.S
        • Donnelly T.M
        • et al.
        In vivo protection against endotoxin by plasma high density lipoprotein.
        Proc Natl Acad Sci USA. 1993; 90: 12040-12044
        • Cockerill G.W
        • Rye K.A
        • Gamble J.R
        • et al.
        High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.
        Arterioscler Thromb Vasc Biol. 1995; 15: 1987-1994
        • Mackness M.I
        • Durrington P.N
        HDL, its enzymes and its potential to influence lipid peroxidation.
        Atherosclerosis. 1995; 115: 243-253
        • Dichtl W
        • Nilsson L
        • Goncalves I
        • et al.
        Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells.
        Circ Res. 1999; 84: 1085-1094
        • Knudsen P
        • Eriksson J
        • Lahdenpera S
        • et al.
        Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.
        Diabetologia. 1995; 38: 344-350
        • Steiner G
        Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis.
        Diabetes Care. 1991; 14: 1077-1081
        • Ridker P.M
        • Rifai N
        • Clearfield M
        • et al.
        Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
        N Engl J Med. 2001; 344: 1959-1965
        • Albert M.A
        • Danielson E
        • Rifai N
        • Ridker P.M
        Effect of statin therapy on C-reactive protein levels.
        JAMA. 2001; 286: 64-70
        • Rosenson R.S
        • Tangney C.C
        • Casey L.C
        Inhibition of proinflammatory cytokine production by pravastatin.
        Lancet. 1999; 353: 983-984
        • Inoue I
        • Goto S
        • Mizotani K
        • et al.
        Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect.
        Life Sci. 2000; 67: 863-876
        • Martin G
        • Duez H
        • Blanquart C
        • et al.
        Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
        J Clin Invest. 2001; 107: 1423-1432
        • Delerive P
        • De Bosscher K
        • Besnard S
        • et al.
        Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1.
        J Biol Chem. 1999; 45: 32048-32054